{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:54:39Z","timestamp":1761155679142},"reference-count":57,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T00:00:00Z","timestamp":1365033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study aimed to compare use of histamine H2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs), 2001\u20132005, in the elderly and social security beneficiaries in Australia (AUS) and Nova Scotia, Canada (NS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prescription dispensing data were collected for all subsidised H2RAs and PPIs. In AUS, dispensing data for concession beneficiaries were obtained from the Pharmaceutical Benefits Scheme database. In NS, data were sourced from the Pharmacare database. Relevant population data were used to convert to World Health Organisation Anatomic Therapeutic Chemical defined daily doses (2005) per 1000 beneficiaries per day (DDD\/1000\/day).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall use of gastroprotective agents was similar and rising in NS and AUS (100\u2013160\u2009DDD\/1000\/day) over this 5\u2010year time window. However, the proportion of this use accounted for by PPIs was far higher in AUS (over 85% by 2005) than in NS (23% rising to 35% over the 5\u2009years). In AUS, PPI use rose from 50 to about 140\u2009DDD\/1000\/day over the 5\u2009years, whereas PPI use in NS rose slowly to less than 60\u2009DDD\/1000\/day by 2005. H2RA use in NS was always high (over 100\u2009DDD\/1000\/day), whereas in AUS, H2RA use fell from 54 to around 24\u2009DDD\/1000\/day over this period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>AUS had much higher use of PPIs than NS over 2001\u20132005. The proportion of PPIs in all gastroprotective agents rose in AUS to be nearly 90%. The differences in utilisation during this time window could lead to differences in health outcomes from either lower gastro\u2010intestinal bleeding risk or higher long\u2010term adverse effects of PPIs. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.3442","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T04:05:24Z","timestamp":1365134724000},"page":"735-743","source":"Crossref","is-referenced-by-count":13,"title":["Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada"],"prefix":"10.1002","volume":"22","author":[{"given":"Susan E.","family":"Tett","sequence":"first","affiliation":[{"name":"School of Pharmacy The University of Queensland  Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Sketris","sequence":"additional","affiliation":[{"name":"College of Pharmacy Dalhousie University  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charmaine","family":"Cooke","sequence":"additional","affiliation":[{"name":"Health Information Office Nova Scotia Department of Health and Wellness  Halifax Nova Scotia Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander Veldhuyzen","family":"van Zanten","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology University of Alberta  Edmonton Alberta Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Barozzi","sequence":"additional","affiliation":[{"name":"School of Pharmacy The University of Queensland  Brisbane QLD Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000331138"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38356.641134.8F"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006036.pub2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04305.x"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.70"},{"issue":"9","key":"e_1_2_8_7_1","first-page":"e228","article-title":"Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting","volume":"16","author":"Heidelbaugh JJ","year":"2010","journal-title":"Am J Manag Care"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.64"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60070-2"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.092129"},{"key":"e_1_2_8_11_1","article-title":"No consistent evidence of differential cardiovascular risk amongst proton\u2010pump inhibitors when used with clopidogrel: meta\u2010analysis","author":"Kwok CS","year":"2012","journal-title":"Int J Cardiol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-011-2007-1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir767"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.giec.2011.07.005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2198"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986711795843245"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04585.x"},{"key":"e_1_2_8_18_1","volume-title":"Public Citizen Petition Urging FDA to Add Warnings to Proton Pump Inhibitors","author":"Nellis E","year":"2011"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.113"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1243"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.12.015"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e328348a56a"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.01.007"},{"key":"e_1_2_8_24_1","volume-title":"Keeping an Eye on Prescription Drugs, Keeping Canadians Safe. Active Monitoring Systems for Drug Safety and Effectiveness in Canada and Internationally","author":"Wiktorowicz M","year":"2010"},{"key":"e_1_2_8_25_1","volume-title":"Ethical and Scientific Issues in Studying the Safety of Approved Drugs","author":"Institute of Medicine of the National Academies","year":"2012"},{"issue":"1","key":"e_1_2_8_26_1","first-page":"1","article-title":"The U.S. Food and Drug Administration's Mini\u2010Sentinel program: status and direction","volume":"21","author":"Platt R","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03410.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.04.009"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1541"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674370805300809"},{"key":"e_1_2_8_31_1","unstructured":"Government of Nova Scotia.Nova Scotia Pharmacare Formulary: Government of Nova Scotia [cited 2012 July 20th]. Available from:http:\/\/www.gov.ns.ca\/health\/Pharmacare\/formulary.asp."},{"key":"e_1_2_8_32_1","unstructured":"Nova Scotia Health. Nova Scotia Pharmacare ProgramsThe Nova Scotia Seniors' Pharmacare Program 2008 [updated February 2008; cited 2012 July 20th]. Available from:http:\/\/www.gov.ns.ca\/health\/Pharmacare\/seniors_pharmacare\/Seniors_Information_Booklet_2008.pdf."},{"key":"e_1_2_8_33_1","unstructured":"Australia. MPharmaceutical Benefits Scheme Statistics: Australian Department of Health & Aging; [cited 2012 July 20th]. Available from:http:\/\/www.medicareaustralia.gov.au\/provider\/pbs\/stats.jsp."},{"key":"e_1_2_8_34_1","volume-title":"Guidelines for ATC Classification and DDD Assignment 2005","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2005"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050431"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.05.019"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68932-0"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03905.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/674607"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.217547"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01995.x"},{"issue":"8","key":"e_1_2_8_42_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1155\/2010\/397610","article-title":"The rate of prescribing gastrointestinal prophylaxis with either a proton pump inhibitor or an H2\u2010receptor antagonist in Nova Scotia seniors starting nonsteroidal anti\u2010inflammatory drug therapy","volume":"24","author":"Superceanu B","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X08315247"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.20.2630"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1685"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.09.006"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1969"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.04.012"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/235476"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1071\/AH040194"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1409"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hcmf.2011.02.008"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2011.110285"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.11.98"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.09.73"},{"key":"e_1_2_8_56_1","volume-title":"Proton Pump Inhibitor Use in Seniors: An Analysis Focusing on Drug Claims, 2001 to 2008","author":"Canadian Institute for Health Information","year":"2009"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1972"},{"key":"e_1_2_8_58_1","volume-title":"Australian Department of Health & Ageing. Expenditure and Prescriptions Twelve Months to 30 June 2011","author":"Policy Pharmaceutical","year":"2011"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.3442","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.3442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:46:18Z","timestamp":1700675178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.3442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,4]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/pds.3442"],"URL":"https:\/\/doi.org\/10.1002\/pds.3442","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,4]]}}}